Labcorp’s Q2: Diagnostics Mix and BLS Momentum Offset Policy Clouds
Revenue up 5.8%, adjusted EPS +15%, and guidance raised, but ACA and PAMA headwinds linger.
LH · Earnings Call · 2026-07-30
Another Strong Quarter, But the Mix Is the Story
Labcorp delivered another solid beat-and-raise quarter. Enterprise revenue grew 5.8% to $3.7 billion, adjusted operating margin expanded 70 basis points to 15.8%, and adjusted EPS rose 14.9% to $4.99. The company lifted its full-year revenue and EPS guidance, citing continued strength in Diagnostics and Biopharma Laboratory Services (BLS). What stands out this quarter is not just the headline numbers, but the changing composition of growth—driven by an increasing emphasis on test per accession, a deeper push into consumer self-pay, and a BLS turnaround that is finally showing up in margins. The diagnostics segment grew 5.5% to $2.9 billion, with organic revenue up 3.6%. Adam Schechter emphasized that the real volume picture is stronger than reported if you account for tests per requisition: “if you would increase that, you would actually see tests actually going up even more.” — Adam Schechter, Chairman and Chief Executive Officer · 2026-07-30 This metric—test per accession—has become a central narrative, as the company leans into higher-value esoteric testing across oncology, neurology, and women’s health. The mix shift is visible in the numbers: Price mix contributed 2.5% to diagnostics growth, with organic price mix at 1.8%. The company is not chasing low-margin consumer deals; instead, it is focusing on specialty testing and hospital partnerships that raise both volume and margin. Patient pay is also becoming a more visible driver. With the launch of MyLabcorp and the expansion of Labcorp OnDemand, Adam noted that direct-to-consumer growth is both durable and margin-accretive: “it's hard to see a way that home collection can get to that level” — Adam Schechter, Chairman and Chief Executive Officer · 2026-07-30 when discussing the limits of self-collection for complex oncology patients—yet the company is clearly investing in the simpler, high-volume consumer segment. Julia Wang added that bad debt remains under control, even as patient responsibility grows: “it was a slight headwind of about 20 to 30 basis points of the diagnostic volume” — Julia Wang, Executive Vice President and Chief Financial Officer · 2026-07-30—a reference to ACA-related utilization, not collection issues.BLS: Early Development Actions Finally Bearing Fruit
The BLS segment delivered a standout quarter, with revenue up 6.5% and adjusted operating margin expanding 130 basis points to 17%. Central Labs continued to drive growth (7.6% organic constant currency), while Early Development returned to positive organic growth of 2.7%. The strategic actions announced in prior quarters—divestitures and site consolidations—are largely complete, and Adam highlighted the improving backlog: “So we've certainly seen that business do a bit better than it has in the prior year or 2.” — Adam Schechter, Chairman and Chief Executive Officer · 2026-07-30 The quarterly book-to-bill hit 1.14, and the trailing 12-month figure improved to 1.03, giving confidence in the second half. This turnaround in strategic action is directly reflected in margins. Julia reiterated that BLS margin expansion will outpace Diagnostics for the full year, helped by top-line growth in Central Labs and the cost actions already taken. The company now expects Early Development to grow in the low single digits for 2026, up from prior expectations of flat.Policy Overhangs: Same Song, Different Verse
The policy backdrop remains a recurring theme, with ACA and PAMA weighing on the outlook. On ACA, Julia confirmed the 30 basis point volume impact assumption for the full year, noting that Q2 saw a slight headwind of 20-30 bps. This is consistent with prior commentary—in the Q1 call, she had said: “we continue to believe that the 30 basis point volume impact is a good estimate to work with.” — Julia Wang, Executive Vice President and Chief Financial Officer · 2026-04-30 The exposure is small (less than 5% of diagnostics volume), but the uncertainty lingers. On PAMA, the company remains in advocacy mode. The data submission deadline is July 31, and Adam noted that visibility into other labs’ submissions won’t come until October. He reiterated the company’s base case assumes a $100 million top and bottom line impact if PAMA goes into effect next year, and that they have contingency plans. This mirrors his October 2025 comments: “we think the prudent strategy is for us to plan that there will be a $100 million impact.” — Adam Schechter, Chairman and Chief Executive Officer · 2025-10-28 The RESULTS Act remains the preferred legislative fix, but progress is uncertain.Capital Allocation and Outlook
The company is deploying capital aggressively—$226 million in acquisitions, $354 million in buybacks, and $59 million in dividends in Q2. With the new $1 billion authorization, the total repurchase capacity is $1.4 billion. Management remains disciplined on deal criteria, seeking first-year accretion and a 2-3 year payback. The strong cash generation supports these moves, and the company’s operating margin reached 10.8% on a GAAP basis, while adjusted margins hit 15.8%—a clear sign of operating leverage. Looking ahead, Labcorp raised the midpoint of enterprise revenue and EPS guidance by $42 million and $0.30, respectively. The implied EPS growth of >11% at the midpoint underscores confidence in the second half. As Adam concluded:The stock has rallied nearly 29% over the past 90 days, reflecting the market’s appreciation for the margin story and the BLS turnaround. The key question is whether the mix shift and cost discipline can offset the impending policy headwinds—a tension that will define the next chapter.All of this has led to us increasing our full year revenue and EPS guidance.